AstraZeneca PLC (AZN)
Pre-Market:
| Previous Close | 75.17 |
| Open | 76.18 |
| Bid | 75.40 x 200 |
| Ask | 75.55 x 200 |
| Day's Range | 75.37 - 76.56 |
| 52 Week Range | 60.47 - 76.58 |
| Volume | |
| Avg. Volume | 6,458,991 |
| Market Cap | 234.021B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 37.37 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.45 (1.92%) |
| Ex-Dividend Date | Feb 22, 2024 |
| 1y Target Est | N/A |
- Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
WILMINGTON, Del., April 29, 2024--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.
- PR Newswire
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual M
- Business Wire
Q1 2024 results
CAMBRIDGE, United Kingdom, April 25, 2024--Q1 Earnings Release (25 April 2024)
